Fresenius Medical Care (FMS)
NYSE:FMS
Want to see FMS full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.62Last Year’s EPS
0.53Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a cautiously positive operational and financial start to 2026: solid top‑line organic growth (4%), strong operating income growth (+10%) and margin expansion, meaningful FME25+ savings (EUR 50m), successful accelerated EUR 1bn share buyback, improved cash generation and clear progress on the 5008X rollout and clinical quality initiatives (90% catheter lock adoption, >100k 5008X treatments). Offsetting these positives are near‑term headwinds: front‑loaded restructuring/special costs (EUR 181m), regulatory pressures in China, U.S. volume challenges driven by weather, ACA subsidy expiry and elevated mortality, and a TDAPA phasing effect that is expected to be a material negative in H2 2026. Management confirmed the full‑year outlook and emphasized the temporary/phasing nature of several negatives, supporting a constructive but cautious tone.Company Guidance
Solid Group Revenue Growth
Organic revenue growth of 4% in Q1 2026 (3% at constant currency), with growth contributions from all three operating segments (Care Delivery organic +6%; Value‑Based Care +3%; Care Enablement +1% organic).
Strong Operating Income and Margin Expansion
Group operating income grew ~10% (constant currency) and group operating income margin expanded ~70 basis points to 10.1%. Care Delivery operating income rose ~26%, with margin improving to 12.1%. Value‑Based Care margin improved by ~100 basis points.
FME25+ Cost Savings Delivery
FME25+ program delivered EUR 50 million in sustainable savings in the quarter and contributed positively to results; related restructuring costs were disclosed as special items but are expected to decline over the year.
Completed Accelerated Share Buyback and Strong Balance Sheet
Completed initial EUR 1.0 billion share buyback ahead of schedule (bought back 24.8 million shares, representing 8.5% of share capital). Net leverage ratio around 2.6x, at the lower end of the 2.5–3.0x target corridor.
Improved Cash Generation
Operating cash flow increased ~39% in Q1 (seasonally low quarter), and free cash flow rose ~94% to EUR 40 million, driven mainly by favorable working capital management.
5008X CAREsystem Rollout and Clinical Innovation
Large‑scale 5008X rollout accelerated: surpassed 100,000 treatments by early April and ~100 clinics converted; on track with production and consumables supply; rollout expected to replace ~20% of machines in 2026 and to drive future clinical and commercial upside.
Clinical Quality Improvements: Catheter Lock Adoption
Around 90% of eligible patients now use an antimicrobial catheter lock solution, correlating with reductions in catheter‑related bloodstream infections and expected downstream decreases in hospitalizations and missed treatments.
Value‑Based Care: Profitability and Quality Recognition
Value‑Based Care reported positive operating income (profitable for the second consecutive quarter), expanded member months, and delivered over $270 million in shared savings with an 88% average quality score across the first three years; AI interventions showed up to 15% fewer hospitalizations and up to 26% fewer missed treatments in highest‑risk patients.
FMS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FMS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $22.03 | $19.64 | -10.86% |
Feb 24, 2026 | $23.92 | $22.04 | -7.85% |
Nov 04, 2025 | $25.63 | $23.63 | -7.82% |
Aug 05, 2025 | $24.26 | $23.76 | -2.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fresenius Medical Care (FMS) report earnings?
Fresenius Medical Care (FMS) is schdueled to report earning on Aug 04, 2026, TBA (Confirmed).
What is Fresenius Medical Care (FMS) earnings time?
Fresenius Medical Care (FMS) earnings time is at Aug 04, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FMS EPS forecast?
FMS EPS forecast for the fiscal quarter 2026 (Q2) is 0.62.